ClinicalTrials.gg
Status unknownNCT02947867STRONGUpdated Oct 31, 2016

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

A Phase 2/3 interventional study of aganirsen in Ischaemic Central Retinal Vein Occlusion and Neovascular Glaucoma, sponsored by Gene Signal SAS. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Gene Signal SAS · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study

Read the detailed description

The STRONG Study is a phase II/III prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre study of aganirsen antisense oligonucleotide, a topical treatment for iCRVO intended to prevent Neovascular Glaucoma (NVG). The study will evaluate the efficacy of two different doses of aganirsen formulated in an eye emulsion in avoiding new vessel formation by blocking the Insulin Receptor Substrate (IRS)-1. Eligible patients will be treated with aganirsen or placebo for a period of 24 weeks. They will also be invited to participate in sub-studies working on the analysis of gonioscopic images, detection of biomarkers for neovascular glaucoma and risk factors for ischaemic central retinal vein occlusion.

02

Conditions studied

  • Ischaemic Central Retinal Vein Occlusion
  • Neovascular Glaucoma

Browse trials for

03

In context

Glaucoma, Neovascular

39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

This study's planned enrollment of 333 is above the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.

Browse Glaucoma, Neovascular studies →

Lead sponsor

This is the only study on the registry with Gene Signal SAS as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following criteria will be considered for enrolment to the trial:

  • Male or female ≥ 18 years
  • IOP in the study eye ≤ 21mmHg
  • Primary ischaemic CRVO or conversion to ischaemic CRVO in the study eye for no longer than 4 weeks
  • Best-corrected visual acuity (BCVA) ETDRS letter score \< 35 (\< 20/200 Snellen equivalent) in the study eye
  • ≥ 10-disc area of retinal capillary obliteration on fluorescein fundus angiography in the study eye (central fundus: macular area as defined by the optic disc and the arcades, an approximate 6000 micron circle around the fovea) and/or large, confluent retinal haemorrhages in the study eye

Must be accompanied by 4 or more out of 6 following criteria:

  • A relative afferent pupillary defect (with a normal fellow eye)
  • ≥ 10 cotton-wool-spots in the study eye
  • Venous tortuosity in the study eye
  • Peripheral visual field defects corresponding to ischaemia (Goldmann perimeter or other semi-automatic kinetic methods) in the study eye
  • Engorged vessels on iris and/or in the chamber angle in the study eye
  • Detectable anterior chamber flare in the study eye

Exclusion criteria

Exclusion Criteria:

Subjects presenting 1 or more of the following criteria will not be enrolled in the trial:

  • Ocular conditions with a poorer prognosis in the fellow eye than in the study eye
  • Primary or secondary glaucoma in the study eye
  • Prior or concomitant ocular treatment with anti-VEGF in the study eye (ranibizumab/bevacizumab is not allowed within the last 45 days, aflibercept within the last 90 days) before screening visit
  • Use of anti-VEGF treatment in the fellow eye during the trial
  • Previous use of intraocular at any time or use of periocular corticosteroids in the study eye within 90 days prior to screening visit
  • History of idiopathic or uveitis in either eye
  • Presence of NVD, NVE or anterior segment neovascularisation (NVA or NVI) in the study eye
  • Previous PRP in the study eye
  • Intraocular surgery (other than intravitreal anti-VEGF treatment) or laser treatment in the study eye within the past 90 days before screening visit
  • Patients with a history of breast cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    aganirsen "low-dose":

    43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily

    Drug: aganirsen

  • Experimental
    aganirsen "high-dose"

    86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)

    Drug: aganirsen

  • Placebo comparator
    aganirsen placebo (vehicle)

    one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily

    Drug: aganirsen

Interventions

  • aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

    Also known as: GS-101

06

What researchers measure

Primary outcomes

  1. NVG component

    Co-primary I: NVG component scored dichotomously (NVG=yes/NVG=no) where "yes" is development of NVI, NVA, NVD, and/or NVE, or rescue treatment; "no" otherwise

    Time frame: Week 24

  2. IOP component

    Co-primary II: IOP component scored dichotomously (failure/success); "failure" is rise in IOP from baseline to week 24 of ≥ 20% to \> 21 or rescue treatment; "success" otherwise

    Time frame: Week 24

Secondary outcomes

  1. Secondary NVG

    The time to development of secondary NVG in the study eye up to week 24 (in case aganirsen does not totally inhibit but slows down the development of NVG).

    Time frame: 24 weeks

  2. Anterior segment neovascularisation

    The time to development of anterior segment neovascularisation (NVI or NVA), NVD or NVE in the study eye, requiring PRP or cryotherapy up to week 24.

    Time frame: 24 weeks

  3. NVG Classification

    NVG Classification at 24 weeks on a scale from 1 (non-NVG) to 6 (most advanced NVG) based on central reading of neovascularisation

    Time frame: 24 weeks

  4. Visual Acuity

    The change from baseline in BCVA (EDTRS letter score) in the study eye to week 24.

    Time frame: 24 weeks

  5. Number of additional needed laser treatments and re-treatments in the study eye at up to week 24

    Number of additional needed laser treatments and re-treatments in the study eye at up to week 24

    Time frame: 24 weeks

  6. Required intensity of laser spots of additional laser treatments and re-treatments in the study eye at up to week 24

    Required intensity of laser spots of additional laser treatments and re-treatments in the study eye at up to week 24

    Time frame: 24 weeks

  7. Retinal non-perfusion area

    The change from baseline in size of retinal non-perfusion areas in the study eye to week 24

    Time frame: 24 weeks

  8. Retinal Thickness

    Absolute change from baseline in retinal thickness in the study eye, assessed by spectral domain optical coherence tomography (SD-OCT) at week 24

    Time frame: 24 weeks

  9. Quality of Life

    The change from baseline in the NEI-VFQ-25 health questionnaire total score to week 24

    Time frame: 24 weeks

  10. Quality of Life on EQ-5D

    The change from baseline in the EQ-5D health questionnaire score to week 24

    Time frame: 24 weeks

  11. Safety: Incidence of treatment-emergent Adverse Events

    Incidence, causality and intensity of adverse events between the treatment arms

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lorenz K, Scheller Y, Bell K, Grus F, Ponto KA, Bock F, Cursiefen C, Flach J, Gehring M, Peto T, Silva R, Tal Y, Pfeiffer N. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. Trials. 2017 Mar 16;18(1):128. doi: 10.1186/s13063-017-1861-3. PubMed 28302155 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Jun 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2016
First posted
Oct 28, 2016
Start
Jan 2017
Primary completionEst.
Jun 2019
CompletionEst.
Dec 2019
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02947867
Lead sponsor
Gene Signal SAS
Collaborators
Johannes Gutenberg University Mainz, University Hospital of Cologne, Moorfields Eye Hospital NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 28, 2016
Start date
Jan 2017
Primary completion
Jun 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Oct 31, 2016

Study contacts

Katrin Lorenz, MD
Contact
katrin.lorenz@unimedizin-mainz.de
+49613117 ext. 4069
Yvonne Scheller, PhD
Contact
yvonne.scheller@unimedizin-mainz.de
+49613117 ext. 3367

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GS 101

Start the discussion